☰

Gary E. Raskob

Affiliations: 
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States 
Area:
Biostatistics Biology, Recreation, Physical Education
Google:
"Gary Raskob"
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Michael Gent grad student 1983-1985 McMaster University (Epi Tree)

Children

Sign in to add trainee
Sean D. Turbeville grad student 2001 University of Oklahoma Health Sciences Center
Amanda J. Cash grad student 2007 University of Oklahoma Health Sciences Center
Jennifer K. Mullens grad student 2011 University of Oklahoma Health Sciences Center

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lanting V, Takada T, Bosch F, et al. (2024) Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thrombosis and Haemostasis
Spyropoulos AC, Raskob GE, Cohen AT, et al. (2022) Association of Bleeding Severity with Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation
Raskob GE, Spyropoulos AC, Spiro TE, et al. (2021) Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. Journal of the American Heart Association. e021579
Lipardi C, Elliott CG, Sugarmann CL, et al. (2021) Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 27: 10760296211053316
Raskob GE, Spyropoulos AC, Cohen AT, et al. (2021) Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. Journal of the American Heart Association. e019459
O'Connell C, Escalante CP, Goldhaber SZ, et al. (2020) Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. The Oncologist
Spyropoulos AC, Ageno W, Albers GW, et al. (2020) Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology. 75: 3140-3147
Spyropoulos AC, Ageno W, Cohen AT, et al. (2020) Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thrombosis and Haemostasis. 120: 924-936
Mulder FI, van Es N, Kraaijpoel N, et al. (2020) Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19]. Thrombosis Research
Weitz JI, Raskob GE, Spyropoulos AC, et al. (2020) Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. Thrombosis and Haemostasis
See more...